Simple Summary Craniopharyngiomas (CPs) currently represent one of the most
challenging diseases to deal with in the group of skull base tumors. Due to their location …

Craniopharyngiomas are commonly classified as low-grade tumors, although they may
harbor a malignant behavior due to their high rate of recurrence and long-term morbidity …

Background As a benign intracranial tumor, craniopharyngioma (CP) treatment has always
been considered a challenging clinical problem. Recently, BRAF V600E mutation in the …

Craniopharyngioma (CP) represent 1.2-4.6% of all intracranial tumors in children and carry
a significant morbidity due to their lesional intimacy with structures involved in neurological …

Background Craniopharyngioma (CP) in adults is a rare benign tumor associated with many
morbidities, with limited contemporary studies to define treatment, and follow-up guidelines …

Pituitary alterations in the Wnt/β-catenin pathway, generally involving the central regulatory
gene CTNNB1. Several authors have shown the efficacy of BRAF and MEK inhibitor therapy …

Background Craniopharyngiomas are benign sellar lesions. Surgical excision of
craniopharyngiomas is difficult because of the surrounding important neurovascular …

Context Outcome of craniopharyngioma is related to its locoregional extension, which
impacts resectability and the risk of surgical complications. To maximize resection and …

Craniopharyngiomas present unique challenges in surgical management due to their
proximity to critical neurovascular structures. This systematic review investigates genetic and …

Rare central nervous system tumors are defined by an incidence rate of less than 6 cases
per 100 000 individuals a year. It comprises a large panel of entities including …